SPY445.87+3.37 0.76%
DIA352.85+3.84 1.10%
IXIC14,897.34+73.91 0.50%

Stifel Initiates Coverage On Verve Therapeutics with Hold Rating, Announces Price Target of $58

Stifel analyst Dae Gon Ha initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Hold rating and announces Price Target of $58.

Benzinga · 09/24/2021 05:21
Stifel analyst Dae Gon Ha initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Hold rating and announces Price Target of $58.